[FGF/FGFR signalling: Implication in oncogenesis and perspectives].
Fiche publication
Date publication
juin 2015
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr VIGNOT Stéphane
Tous les auteurs :
Flippot R, Kone M, Magné N, Vignot S
Lien Pubmed
Résumé
Deregulation of FGF (fibroblast growth factor)/FGFR (fibroblast growth factor receptor) signalling leads to the promotion of several oncogenic mechanisms: proliferation, epithelial-mesenchymal transition, cytoskeleton modifications, migration and angiogenesis. Deregulation of this pathway is reported in various cancers at early stages, and can therefore be responsible for the emergence of the hallmarks of cancer. It is necessary to precise downstream pathways of FGFR signalling to understand its oncogenic potential. We will then describe its implications in different cancer types. Oncogenic mechanisms will be studied through the example of melanoma, in which deregulation of FGF/FGFR pathway is considered as a driver event and occurs in nearly 90% of cases. The FGF/FGFR signalling pathway is a putative therapeutic target. Numerous agents are in active development, operating through a selective or multi-targeted approach. Recent studies have shown rather disappointing results in non-selected patients, but promising results in patients with FGF/FGFR pathway alterations. A careful screening of patients is the key to a valuable evaluation of these new targeted molecular therapies.
Mots clés
Amplification, FGF receptor, Melanoma, Molecular targeted therapy, Mutation, Mélanome, Thérapie moléculaire ciblée
Référence
Bull Cancer. 2015 06;102(6):516-26